Halozyme Therapeutics reported $1.85B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Baxter International USD 6.83B 163M Sep/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
MannKind USD 240.48M 5.24M Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Pfizer USD 45.01B 3.65B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
United Therapeutics USD 2.88B 603.5M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025